Vaxil Bio Company Insiders
| VXL Stock | CAD 0.01 0.00 0.00% |
Vaxil Bio employs about 3 people. The company is managed by 3 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive. Recap of Vaxil Bio's management performance can provide insight into the venture performance.
Vaxil |
Vaxil Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.1018) % which means that it has lost $0.1018 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2026) %, meaning that it generated substantial loss on money invested by shareholders. Vaxil Bio's management efficiency ratios could be used to measure how well Vaxil Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.0003 in 2024. Return On Capital Employed is likely to drop to -0.3 in 2024. At this time, Vaxil Bio's Net Tangible Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 88 K in 2024, whereas Total Assets are likely to drop slightly above 853.8 K in 2024.Common Stock Shares Outstanding is likely to climb to about 143.8 M in 2024, whereas Net Loss is likely to drop (1.2 M) in 2024.
Vaxil Bio Workforce Comparison
Vaxil Bio is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1.11 Million. Vaxil Bio adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Vaxil Bio Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Vaxil Bio Price Series Summation is a cross summation of Vaxil Bio price series and its benchmark/peer.
Vaxil Bio Notable Stakeholders
A Vaxil Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vaxil Bio often face trade-offs trying to please all of them. Vaxil Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vaxil Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| David Goren | CEO Chairman | Profile | |
| Yuval Avnir | Head CEO | Profile | |
| Riva MD | Scientist Board | Profile |
About Vaxil Bio Management Performance
The success or failure of an entity such as Vaxil Bio often depends on how effective the management is. Vaxil Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vaxil management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vaxil management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.29) | (0.30) |
Please note, the imprecision that can be found in Vaxil Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vaxil Bio. Check Vaxil Bio's Beneish M Score to see the likelihood of Vaxil Bio's management manipulating its earnings.
Vaxil Bio Workforce Analysis
Traditionally, organizations such as Vaxil Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vaxil Bio within its industry.Vaxil Bio Manpower Efficiency
Return on Vaxil Bio Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 84.7K | |
| Net Loss Per Executive | 84.7K | |
| Working Capital Per Employee | 297K | |
| Working Capital Per Executive | 297K |
Additional Tools for Vaxil Stock Analysis
When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.